vimarsana.com
Home
Live Updates
Roivant: Oral Brepocitinib Fails To Meet Primary Endpoint In Phase 2 Study : comparemela.com
Roivant: Oral Brepocitinib Fails To Meet Primary Endpoint In Phase 2 Study
Roivant (ROIV) and Priovant announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52.
Related Keywords
Matt Gline ,
More Such Health News ,
Systemic Lupus Erythematosus Responder Index ,
Systemic Lupus Erythematosus ,
Roivant ,
Riovant ,
comparemela.com © 2020. All Rights Reserved.